Novel Real Time Polymerase Chain Reaction Approach for Rapid Detection of the Residual Escherichia coli Genomic DNA in Biopharmaceutical Products Establishment of Real Time Polymerase Chain Reaction to Detect Residual gDNA

T. Farivar, Babak Mamnoon, M. K. Arzenani, D. Ilghari
{"title":"Novel Real Time Polymerase Chain Reaction Approach for Rapid Detection of the Residual Escherichia coli Genomic DNA in Biopharmaceutical Products Establishment of Real Time Polymerase Chain Reaction to Detect Residual gDNA","authors":"T. Farivar, Babak Mamnoon, M. K. Arzenani, D. Ilghari","doi":"10.17795/BHS-26375","DOIUrl":null,"url":null,"abstract":"Background: Contamination of therapeutic recombinant proteins with residual host cell DNA must be controlled under the regulatory standards. Objectives: The current study established a new rapid, sensitive real time polymerase chain reaction (PCR) approach to measure the reliably of the residual Escherichia coli (E. coli) host cell genomic DNA in the recombinant streptokinase and alfa interferon preparations. Materials and Methods: In this assay, a specific primer pair was utilized to amplify a 115 base pair sequence inside the E. coli 16S rRNA using SYBR Green Chemistry. This method enabled the authors to detect a very small quantity of the residual genomic DNA, as low as 0.8 pg, in the protein-based drugs. This method can, therefore, offer a dependable way to quantitatively analyze the major contaminant of biopharmaceutical products, the host cell DNA, during the manufacturing process. Results: SYBR Green PCR master mix may contain a source of DNA contamination during its manufacturing process. Conclusions: The current study data showed that E. coli host cell DNA contamination in streptokinase and alfa interferon manufactured in the Pasteur institute of Iran is much lower than the safety limits suggested by the FDA.","PeriodicalId":8849,"journal":{"name":"Biotechnology and Health Sciences","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2014-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biotechnology and Health Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17795/BHS-26375","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Background: Contamination of therapeutic recombinant proteins with residual host cell DNA must be controlled under the regulatory standards. Objectives: The current study established a new rapid, sensitive real time polymerase chain reaction (PCR) approach to measure the reliably of the residual Escherichia coli (E. coli) host cell genomic DNA in the recombinant streptokinase and alfa interferon preparations. Materials and Methods: In this assay, a specific primer pair was utilized to amplify a 115 base pair sequence inside the E. coli 16S rRNA using SYBR Green Chemistry. This method enabled the authors to detect a very small quantity of the residual genomic DNA, as low as 0.8 pg, in the protein-based drugs. This method can, therefore, offer a dependable way to quantitatively analyze the major contaminant of biopharmaceutical products, the host cell DNA, during the manufacturing process. Results: SYBR Green PCR master mix may contain a source of DNA contamination during its manufacturing process. Conclusions: The current study data showed that E. coli host cell DNA contamination in streptokinase and alfa interferon manufactured in the Pasteur institute of Iran is much lower than the safety limits suggested by the FDA.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
新型实时聚合酶链式反应快速检测生物制药产品中残留大肠杆菌基因组DNA的方法
背景:治疗性重组蛋白与宿主细胞DNA残留的污染必须控制在监管标准之下。目的:建立一种新的快速、灵敏的实时聚合酶链反应(PCR)方法,可靠地测定重组链激酶和α干扰素制剂中残留的大肠杆菌(E. coli)宿主细胞基因组DNA。材料和方法:在本实验中,使用SYBR Green Chemistry,利用特定的引物对扩增大肠杆菌16S rRNA中的115碱基对序列。这种方法使作者能够在蛋白质药物中检测到非常少量的残留基因组DNA,低至0.8 pg。因此,该方法可以提供一种可靠的方法来定量分析生物制药产品在生产过程中的主要污染物——宿主细胞DNA。结果:SYBR Green PCR母品在生产过程中可能含有DNA污染源。结论:目前的研究数据显示,伊朗巴斯德研究所生产的链激酶和α干扰素中大肠杆菌宿主细胞DNA污染远低于FDA建议的安全限值。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
The Effect of Myricetin Flavonoid on the Expression of Fyn Gene in Melanoma Cells (A375) No Association Between His 447 His Polymorphism of PPARγ Gene and Osteoporosis in Iranian Postmenopausal Women Evaluation of MexB and MexY Genes Expression in Carbapenem-Resistant Pseudomonas aeruginosa Strains Isolated from Educational Hospitals of Qazvin and Tehran, Iran Evaluation of Thermal Comfort in an Iranian Educational Hospital Using PMV- PPD Model Telemedicine is Cost Effective Compared with Standard Care in Type 2 Diabetes Mellitus - A Randomized Trial with an Economic Analysis in an Outpatient Clinic
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1